Wagner, J.N.; Roeper, J.; Heukamp, L.; Falk, M.; Willborn, K.; Griesinger, F.
Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy. Biomedicines 2024, 12, 688.
https://doi.org/10.3390/biomedicines12030688
AMA Style
Wagner JN, Roeper J, Heukamp L, Falk M, Willborn K, Griesinger F.
Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy. Biomedicines. 2024; 12(3):688.
https://doi.org/10.3390/biomedicines12030688
Chicago/Turabian Style
Wagner, Jan Nicolai, Julia Roeper, Lukas Heukamp, Markus Falk, Kay Willborn, and Frank Griesinger.
2024. "Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy" Biomedicines 12, no. 3: 688.
https://doi.org/10.3390/biomedicines12030688
APA Style
Wagner, J. N., Roeper, J., Heukamp, L., Falk, M., Willborn, K., & Griesinger, F.
(2024). Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy. Biomedicines, 12(3), 688.
https://doi.org/10.3390/biomedicines12030688
